Earnings Call · Q2 FY2021·2021-07-29

Q2 21EPS +1.96%·Rev n/aQ1 21EPS +5.56%·Rev n/aQ4 20EPS -70.00%·Rev n/aQ3 20EPS +38.46%·Rev n/a⚠ consensus missing

ABEONA THERAPEUTICS INC. ABEO

Gregory Gin — Vice President of Investor Relations and Corporate Communications

Michael Amoroso — Chief Executive Officer

I'd like to begin this morning with a review of our 3 strategic priorities from this management team in 2021

Edward Carr — Chief Financial Officer

−3.1%1d on move date−3.5% vs SPY3d+0.8%5d−5.5%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ABEO calls or request research access.

More ABEO calls Browse calls Request research access